glp-1-based therapy Redefining Obesity Management: Beyond GLP-1 Monotherapy 🩺 The therapeutic landscape for obesity and Type 2 Diabetes is evolving rapidly with the emergence of dual-hormone agonists. While semaglutide (GLP-1 RA) has demonstrated landmark Glucagon-Like Peptide-1 Based Therapies: A

GLP-1 RAs have pleiotropic actions, with intervention on multiple regulation mechanisms

Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-beta1 in monolayer and insulin-like growth factor-I in a three-dimensional matrix

Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease

MSM (methylsulfonylmethane) is commonly in supplements for joint and muscle pain, although the evidence behind it has been limited

Understanding how alcohol interacts with GLP-1 treatments is crucial if you want to stay on track and get the most from your medication

10.1124/jpet.112.202903 137 KanoskiS